Investor Relations

Corporate Profile

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGelTM,a reverse-thermal sustained-release, hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
PFIC Annual Information Statement